1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. SGLT

SGLT

SGLT (Sodium-dependent glucose cotransporters) are a family of glucose transporter found in the intestinal mucosa (enterocytes) of the small intestine (SGLT1) and the proximal tubule of the nephron (SGLT2 in PCT and SGLT1 in PST). SGLT contribute torenal glucose reabsorption. In the kidneys, 100% of the filtered glucose in the glomerulus has to be reabsorbed along the nephron (98% in PCT, via SGLT2). In case of too high plasma glucose concentration (hyperglycemia), glucose is excreted in urine (glucosuria); because SGLT are saturated with the filtered monosaccharide. Glucose is never secreted by the nephron. There are two most well known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. Inhibition of SGLT2 leads to a reduction in blood glucose levels. Therefore, SGLT2 inhibitors have potential use in the treatment of type II diabetes.

SGLT Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-15409
    Empagliflozin Inhibitor 99.90%
    Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
  • HY-10450
    Dapagliflozin Inhibitor 99.85%
    Dapagliflozin (BMS-512148) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
  • HY-10451
    Canagliflozin Inhibitor 99.61%
    Canagliflozin is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
  • HY-N0143
    Phlorizin Inhibitor
    Phlorizin is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor.
  • HY-N0142
    Phloretin Inhibitor 99.70%
    Phloretin(NSC 407292; RJC 02792) is a dihydrochalcone, a type of natural phenols. Phloretin inhibits the active transport of glucose into cells by SGLT1 and SGLT2.
  • HY-101782
    HSK0935 Inhibitor
    HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid Inhibitor 99.98%
    Ertugliflozin (PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. A drug for the treatment of type 2 diabetes mellitus.
  • HY-15516
    Sotagliflozin Inhibitor 99.99%
    Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
  • HY-15461
    Ertugliflozin Inhibitor 99.80%
    Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. A drug for the treatment of type 2 diabetes mellitus.
  • HY-I0383
    Canagliflozin hemihydrate Inhibitor 99.95%
    Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.
  • HY-13413
    Tofogliflozin hydrate Inhibitor 99.41%
    Tofogliflozin(CSG-452) hydrate is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.
  • HY-17604
    Bexagliflozin Inhibitor 99.48%
    Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) Inhibitor 99.61%
    Dapagliflozin (2S)-1,2-propanediol, hydrate is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine.
  • HY-109092
    Licogliflozin Inhibitor 98.53%
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
  • HY-14894
    Ipragliflozin Inhibitor 98.67%
    Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
  • HY-14894A
    Ipragliflozin L-Proline Inhibitor
    Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
  • HY-109018
    Velagliflozin Inhibitor
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
  • HY-14902
    Tofogliflozin Inhibitor
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.